Both in Biotechnology
Humacyte vs enGene Therapeutics
Over the past year HUMA returned −75.3% and ENGN returned −78.9%; their daily moves had a correlation of 0.00.
HUMA −75.3% ENGN −78.9%Growth of $1, one year, split-adjusted
| Metric | HUMA | ENGN |
|---|---|---|
| Price | $0.3928 | $1.46 |
| Market cap | $109.1M | $97.8M |
| Today | −4.47% | −4.58% |
| 1 month | −24.7% | −24.7% |
| 6 months | −57.5% | −80.8% |
| Year to date | −59.1% | −83.8% |
| 1 year | −75.8% | −79.0% |
| Revenue growth (YoY) | +34.9% | — |
| Gross margin | −203.2% | — |
| Net margin | −9064.5% | — |
| P/E (TTM) | — | — |
| Price / sales | 51.4× | — |
| Net cash | $13.7M | $241.0M |
| Dividend yield | — | — |
| Volatility (60d) | 106.1% | 52.5% |
| Short % of float | 11.9% | 3.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).